Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | |
| Sales | 586 |
| Gross Profit | 586 |
| Operating Expenses | 258 |
| Operating Income | 328 |
| Other Income | -3 |
| Pre-tax Income | 325 |
| Income Tax | 48 |
| Net Income Continuous | 277 |
| Net Income | $277 |
| EPS Basic Total Ops | 12.01 |
| EPS Basic Continuous Ops | 10.58 |
| EPS Diluted Total Ops | 9.01 |
| EPS Diluted Continuous Ops | 10.01 |
| EBITDA(a) | $328 |